The Nature-published validation study (observational design, n=696 diverse participants, 192k+ videos for training) demonstrates remote photoplethysmography (rPPG) via front-camera captures during unlocks achieving <10% error versus ECG across skin tones, outperforming many wearables in accessibility. Yet this understates limitations: no RCT evidence links daily rPPG-derived resting heart rate trends to reduced cardiovascular events, unlike the Apple Heart Study (observational, n=419,297) which flagged AFib but required confirmatory patches. The MedicalXpress coverage overlooks real-world confounders like variable lighting, motion artifacts, and phone camera heterogeneity that could erode accuracy beyond controlled tests. Broader patterns reveal an under-covered pivot from clinic-centric care to always-on device ecosystems, echoing Fitbit's large-scale activity data (observational, millions of users) showing resting HR correlations with mortality—but smartphone ubiquity (69% global ownership) amplifies equity gains while exposing darker-skinned users to prior tech biases now mitigated here. Privacy protocols (on-device processing, manual upload) address consent but ignore downstream data monetization risks seen in other mHealth apps; without larger, longitudinal RCTs and conflict-of-interest disclosures from tech partners, claims of reaching billions remain aspirational rather than evidence-based.